Roche mit sehr gutem Jahresergebnis für 2019
30 janv. 2020 01h00 HE
|
F. Hoffmann-La Roche Ltd
Basel, 30. Januar 2020 Konzernverkäufe steigen um 9%1 zu konstanten Wechselkursen und 8% in Schweizer Franken, Hauptwachstumsträger sind neue Produkte, deren Verkäufe den Umsatzrückgang infolge des...
Roche fait état d’excellents résultats pour 2019
30 janv. 2020 01h00 HE
|
F. Hoffmann-La Roche Ltd
Bâle, le 30 janvier 2020 Le chiffre d’affaires consolidé augmente de 9%1 à taux de change constants et de 8% en francs suisses, sous l’impulsion des nouveaux produits, dont les ventes ont plus que...
Roche reports very strong results in 2019
30 janv. 2020 01h00 HE
|
F. Hoffmann-La Roche Ltd
Basel, 30 January 2020 Group sales increase 9%1 at constant exchange rates and 8% in Swiss francs, driven by new products, more than compensating for impact of competition from biosimilars...
Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer
27 janv. 2020 01h00 HE
|
F. Hoffmann-La Roche Ltd
·Application is being reviewed under FDA’s Real-Time Oncology Review pilot programme Basel, 27 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the completion of a supplemental...
Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer
24 janv. 2020 01h00 HE
|
F. Hoffmann-La Roche Ltd
Basel, 24 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMvigor010 study evaluating Tecentriq® (atezolizumab) as an adjuvant (after surgery) monotherapy...
Roche’s Risdiplam meets primary endpoint in pivotal FIREFISH trial in infants with type 1 spinal muscular atrophy
23 janv. 2020 01h00 HE
|
F. Hoffmann-La Roche Ltd
Risdiplam demonstrated statistically significant and medically meaningful motor milestone improvement in infants with Type 1 SMANo treatment related safety findings leading to withdrawal seen in any...
European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma
21 janv. 2020 01h00 HE
|
F. Hoffmann-La Roche Ltd
Novel combination regimen includes first-in-class antibody-drug conjugate that specifically targets CD79b Targeted off-the-shelf treatment provides much-needed new option for people with relapsed or...
Roche and Illumina partner to broaden patient access to genomic testing
13 janv. 2020 11h55 HE
|
F. Hoffmann-La Roche Ltd
Partnership to leverage Illumina’s extensive decentralised installed base with Roche’s expertise in assay development and to provide broad access to clinical oncology next-generation...
Roche enters licensing agreement with Sarepta Therapeutics to improve the lives of patients living with Duchenne muscular dystrophy
23 déc. 2019 01h00 HE
|
F. Hoffmann-La Roche Ltd
Roche obtains the exclusive right to launch and commercialize SRP-9001, Sarepta’s investigational micro-dystrophin gene therapy for Duchenne muscular dystrophy (DMD) outside the United States At...
European Commission approves Roche’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
19 déc. 2019 01h00 HE
|
F. Hoffmann-La Roche Ltd
Kadcyla in early breast cancer represents a new option after neoadjuvant treatment for this group of patients who are known to have a worse prognosisApproval based on KATHERINE trial data showing...